Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)

NCT00042653 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00042653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2002
Completion date
July 31, 2003
Enrollment
380 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, secondary hyperparathyroidism